Teva adds exec VPs
Teva expands the duties of two executives with appointment to a new Office of the CEO, the company announces March 7. George Barrett, president of Teva North America, takes on the additional role of exec VP-global pharmaceutical markets, and Amir Elstein, VP-global specialty pharmaceutical products, gains a new post as exec VP-global resources. The two report to CEO Shlomo Yanai, who succeeded Israel Makov earlier this year...
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.